Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham CorpfiledCriticalSmithkline Beecham Corp
Priority to CO96036764ApriorityCriticalpatent/CO4700451A1/en
Publication of CO4700451A1publicationCriticalpatent/CO4700451A1/en
El compuesto dimaleato de N,N-dietil-8,8-dipropil-2-azaspiro[4.5]-decano-2-propanamina.Una composición farmacéutica que comprende dimaleato de N,N-dietil-8,8-dipropil-2- azaspiro[4.5]-decano-2-propanamina y un vehículo o diluyente aceptable farmacéuticamente.Un método para inducir inmunomodulación que comprende administrar una cantidad, eficaz como inmunomodulador, de dimaleato de N,N-dietil-8,8- dipropil-2-azaspiro[4.5]-decano-2-propanamina, a un paciente que necesite tal tratamiento.The compound N, N-diethyl-8,8-dipropyl-2-azaspiro [4.5] -decane-2-propanamine dimaleate. A pharmaceutical composition comprising N, N-diethyl-8,8-dipropyl-2- dimaleate. azaspiro [4.5] -decane-2-propanamine and a pharmaceutically acceptable carrier or diluent. A method of inducing immunomodulation comprising administering an immunomodulatory amount of N, N-diethyl-8,8-dipropyl-2-dimaleate. azaspiro [4.5] -decane-2-propanamine, to a patient in need of such treatment.
CO96036764A1996-07-121996-07-12
N, N-DIETHYL-8 DIMALEATE, 8-DIPROPIL-2-AZASPIRO [4.5] DECANE-2-PROPANAMINE
CO4700451A1
(en)
A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE
(54) Heteroaryl Succinamides, Pharmaceutical Compositions Containing the Same and Methods for Treatment of the Diseases Caused by Metalloproteinase Activity